Immunogenicity of multi-epitope DNA and peptide vaccine candidates based on core, E2, NS3 and NS5B HCV epitopes in BALB/c mice

Hepatitis Monthly

Volumn 14, Issue 10, 2014, Pages

  Sabet, Leila Pishraft ^a,b   Taheri, Tahereh ^c   Memarnejadian, Arash ^c   Azad, Talat Mokhtari ^a   Asgari, Fatemeh ^a   Rahimnia, Ramin ^d   Alavian, Seyed Moayed ^e,f   Rafati, Sima ^c   Rad, Katayoun Samimi ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b RAZI VACCINE AND SERUM RESEARCH INSTITUTE   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

^d Faculty of Advance Technology in Medicine   (Iran)

^e BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f Middle East Liver Diseases Center (MELD Centers)   (Iran)

Author keywords

Electroporation; Epitope; Prime Boost; Vaccine

Indexed keywords

CORE PROTEIN; E2 CORE PROTEIN; EPITOPE; GAMMA INTERFERON; HEPATITIS VACCINE; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; MONTANIDE ISA 720; MULTI EPITOPE DNA VACCINE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5B; PEPTIDE VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY DETECTION; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA SEQUENCE; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION; HEPATITIS C; HUMORAL IMMUNITY; IMMUNOGENICITY; MOLECULAR CLONING; MOUSE; NONHUMAN; TH1 CELL; VACCINATION;

EID: 84908249805     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.22215     Document Type: Article

References (43)

1. Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, Part one: Advances in basic knowledge for hepatitis C virus vaccine design. Expert Opin Ther Pat. 2011;21(12):1811-30.
2. Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol. 2007;25:71-99.
3. Ippolito G, Capobianchi MR, Lanini S, Antonelli G. Is hepatitis C virus eradication around the corner only 25 years after its discovery? Int J Antimicrob Agents. 2014:[Epub ahead of Print].
4. Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol. 2011;54(6):1273-85.
5. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5(3):215-29.
6. Smyk-Pearson S, Tester IA, Lezotte D, Sasaki AW, Lewinsohn DM, Rosen HR. Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design. J Infect Dis. 2006;194(4):454-63.
7. Vertuani S, Bazzaro M, Gualandi G, Micheletti F, Marastoni M, Fortini C, et al. Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur J Immunol. 2002;32(1):144-54.
8. Suhrbier A. Polytope vaccines for the codelivery of multiple CD8 T-cell epitopes. Expert Rev Vaccines. 2002;1(2):207-13.
9. Iglesias MC, Mollier K, Beignon AS, Souque P, Adotevi O, Lemonnier F, et al. Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo. Mol Ther. 2007;15(6):1203-10.
10. Martin P, Simon B, Lone YC, Chatel L, Barry R, Inchauspe G, et al. A vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus. Vaccine. 2008;26(20):2471-81.
11. Huang XJ, Lu X, Lei YF, Yang J, Yao M, Lan HY, et al. Cellular immunogenicity of a multi-epitope peptide vaccine candidate based on hepatitis C virus NS5A, NS4B and core proteins in HHD-2 mice. J Virol Methods. 2013;189(1):47-52.
12. Yang Y, Kuang Y, Liu Y, Li W, Jiang Z, Xiao L, et al. Immunogenicity of multiple-epitope antigen gene of HCV carried by novel biodegradable polymers. Comp Immunol Microbiol Infect Dis. 2011;34(1):65-72.
13. Arashkia A, Roohvand F, Memarnejadian A, Aghasadeghi MR, Rafati S. Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice. Virus Genes. 2010;40(1):44-52.
14. Memarnejadian A, Roohvand F. Fusion of HBsAg and prime/ boosting augment Th1 and CTL responses to HCV polytope DNA vaccine. Cell Immunol. 2010;261(2):93-8.
15. Subbramanian RA, Kuroda MJ, Charini WA, Barouch DH, Costantino C, Santra S, et al. Magnitude and diversity of cytotoxic-T-lymphocyte responses elicited by multiepitope DNA vaccination in rhesus monkeys. J Virol. 2003;77(18):10113-8.
16. Tine JA, Firat H, Payne A, Russo G, Davis SW, Tartaglia J, et al. Enhanced multiepitope-based vaccines elicit CD8+ cytotoxic T cells against both immunodominant and cryptic epitopes. Vaccine. 2005;23(8):1085-91.
17. Qiu Q, Wang RY, Jiao X, Jin B, Sugauchi F, Grandinetti T, et al. Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants. Vaccine. 2008;26(43):5527-34.
18. Roohvand F, Aghasadeghi MR, Sadat SM, Budkowska A, Khabiri AR. HCV core protein immunization with Montanide/CpG elicits strong Th1/Th2 and long-lived CTL responses. Biochem Biophys Res Commun. 2007;354(3):641-9.
19. Weiland O, Ahlen G, Diepolder H, Jung MC, Levander S, Fons M, et al. Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C. Mol Ther. 2013;21(9):1796-805.
20. Kennedy JS, Co M, Green S, Longtine K, Longtine J, O'Neill MA, et al. The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine. 2008;26(35):4420-4.
21. Duenas-Carrera S. DNA vaccination against hepatitis C. Curr Opin Mol Ther. 2004;6(2):146-50.
22. Diepolder HM, Gerlach JT, Zachoval R, Hoffmann RM, Jung MC, Wierenga EA, et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol. 1997;71(8):6011-9.
23. Shirai M, Okada H, Nishioka M, Akatsuka T, Wychowski C, Houghten R, et al. An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol. 1994; 68(5):3334-42.
24. Ward S, Lauer G, Isba R, Walker B, Klenerman P. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol. 2002;128(2):195-203.
25. Zhang P, Wu CG, Mihalik K, Virata-Theimer ML, Yu MY, Alter HJ, et al. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci U S A. 2007;104(20):8449-54.
26. Zhang P, Zhong L, Struble EB, Watanabe H, Kachko A, Mihalik K, et al. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci U S A. 2009;106(18):7537-41.
27. Zali MR, Mayumi M, Raoufi M, Nowroozi A. Hepatitis C virus genotypes in the Islamic Republic of Iran: a preliminary study. East Mediterr Health J. 2000;6(2-3):372-7.
28. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2000;13(2):223-35.
29. Chen KY, Liu J, Ren EC. Structural and functional distinctiveness of HLA-A2 allelic variants. Immunol Res. 2012;53(1-3):182-90.
30. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999;50(3-4):213-9.
31. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994;152(1):163-75.
32. Ikram A, Anjum S, Tahir M. In Silico Identification and Conservation Analysis of B-cell and T-Cell Epitopes of Hepatitis C Virus 3a Genotype Enveloped Glycoprotein 2 From Pakistan: A Step Towards Heterologous Vaccine Design. Hepat Mon. 2014;14(6).
33. Abdian N, Gholami E, Zahedifard F, Safaee N, Rafati S. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis. Exp Parasitol. 2011;127(3):627-36.
34. Petrushina I, Tran M, Sadzikava N, Ghochikyan A, Vasilevko V, Agadjanyan MG, et al. Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice. Neurosci Lett. 2003;338(1):5-8.
35. Yao ZQ, Eisen-Vandervelde A, Waggoner SN, Cale EM, Hahn YS. Direct binding of hepatitis C virus core to gC1qR on CD4+ and CD8+ T cells leads to impaired activation of Lck and Akt. J Virol. 2004;78(12):6409-19.
36. Lohr HF, Schmitz D, Arenz M, Weyer S, Gerken G, Meyer zum Buschenfelde KH. The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies. J Hepatol. 1999;31(3):407-15.
37. Park SH, Yang SH, Lee CG, Youn JW, Chang J, Sung YC. Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost. Vaccine. 2003;21(31):4555-64.
38. Chang KM, Thimme R, Melpolder JJ, Oldach D, Pemberton J, Moorhead-Loudis J, et al. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology. 2001;33(1):267-76.
39. Zhu F, Eckels DD. Functionally distinct helper T-cell epitopes of HCV and their role in modulation of NS3-specific, CD8+/tetramer positive CTL. Hum Immunol. 2002;63(9):710-8.
40. Shi L, Liu S, Fan GX, Sheng L, Ren HX, Yuan YK. Effective induction of type 1 cytotoxic T cell responses in mice with DNA vaccine encoding two hepatitis C virus cytotoxic T lymphocyte epitopes. Viral Immunol. 2006;19(4):702-11.
41. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001;194(10):1395-406.
42. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol. 2000;18:927-74.
43. Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities. Expert Opin Ther Pat. 2012;22(4):391-415.